top of page

BRONZE

Vivet Therapeutics

Vivet Therapeutics is a clinical-stage biotech company developing novel and long-lasting gene therapies for rare, inherited liver metabolic diseases.

Vivet’s clinical program, VTX-801, is a novel investigational gene therapy for Wilson disease (WD). This is a rare genetic disorder caused by a mutation in the ATP7B gene that prevents the body from regulating copper, causing severe hepatic damage, neurologic symptoms, and potential death. VTX-801 has received Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) and the European Commission (EC).


Vivet’s clinical program, VTX-PID, is aimed at depleting Neutralizing Antibodies (NAbs) levels for a given AAV serotype. VTX-PID is advancing in a Phase 1 study in Nabs+ subjects and has demonstrated an improvement of the liver transduction in Nab+ animal models.


VTX-806 is in pre-clinical development for Cerebro Tendinous Xanthomatosis (CTX). This is a rare genetic disorder caused by mutations in the CYP27A1 gene that affects the body’s ability to metabolize cholesterol and bile acids. It is characterized by a buildup of cholestanol in the blood and tissues, which can accumulate in the brain, tendons, eyes, and arteries. VTX-806 received ODD by the EC in September 2024 and is demonstrating its potential in in vivostudies as an alternative treatment option for patients affected by the burden of CTX.


Vivet develops these technologies through its partnership and exclusive license agreements with the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.



bottom of page